Importantly, considering that P2Y12R are present on glomus cells and have a fundamental role in chemoreflex activation already during moderate arterial pO2 reduction, which can be attributed to respiratory diseases, such as COPD [60]; antiplatelet medication may inadvertently influence peripheral chemoreflex sensitivity, consequently the clinical treatment benefit might be reduced for patients with chronic respiratory morbidities (Fig. 6). Here, P2RY12 is linked to chronic obstructive pulmonary disease.